The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation

Virology

Volumn 326, Issue 1, 2004, Pages 20-28

  Goncalves, Loredana ^a   Albarran, Benibelks ^a   Salmen, Siham ^a   Borges, Lerida ^a   Fields, Howard ^b   Montes, Henry ^a   Soyano, Andres ^c   Diaz, Yuleima ^c   Berrueta, Lisbeth ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

CD25; CD40L; CD69; HBsAg; HBV vaccine; Nonresponders; T cell activation

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CORRELATION COEFFICIENT; CYTOKINE PRODUCTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE ACTIVATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD40 LIGAND; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TREATMENT FAILURE; VACCINATION;

HEPATITIS B VIRUS;

EID: 3242687250     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.04.042     Document Type: Article

References (31)

1. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. 87:1989;14S-20S
2. Avanzini M.A., Belloni C., Soncini R., Ciardelli L., de Silvestri A., Pistorio A., Tinelli C., Maccario R., Rondini G. Increment of recombinant hepatitis B surface antigen-specific T-cell precursors after revaccination of slow responder children. Vaccine. 19:2001;2819-2824
3. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+ CD25 height regulatory cells in human peripheral blood. J. Immunol. 167:2001;1245-1253
4. Barnaba V., Franco A., Alberti A., Benvenuto R., Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature. 345:1990;258-260
5. Bocher W., Herzog S., Schlaak J., Hermenn K., Friedrich H. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology. 29:1999;238-244
6. Chedid M., Deulofeut H., Yunis D., Lara-Marquez M., Salazar M., Deulofeut R., Awdeh Z., Alper C., Yunis E. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum. Immunol. 58:1997;42-51
7. Chisari F. Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol. 156:2000;1117-1132
8. Chisari F., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29-60
9. Coates T., Wilson R., Patrick G., Andre F., Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther. 23:2001;392-403
10. del Canho R., Grosheide P.M., Schalm S.W., de Vries R.R., Heijtink R.A. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J. Hepatol. 20:1994;483-486
11. Desombere I., Gijbels Y., Verwulgen A., Leroux G. Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines. Clin. Exp. Immunol. 122:2000;390-399
12. Frauwirth K., Thompson C. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109:2002;295-299
13. Grewal I., Flavell T. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153:1996;85-106
14. Grewal I., Flavell R. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:1998;111-135
15. Jafarzadeh A., Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin. Exp. Immunol. 131:2003;451-456
16. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:2002;251-262
17. Kardar G., Tehrani J., Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand. J. Immunol. 55:2002;311-314
18. Kruskall M.S., Alper C.A., Awdeh Z., Yunis E.J., Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 174:1992;495-502
19. Larsen C., Xu J., Lee S., Dubey D., Uko G., Yunis E., Alper C. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine. 18:2000;3021-3030
20. Leroux-Roels G., Desombere I., Cobbaut L., Petit M.A., Desmons P., Hauser P., Delem A., De Grave D., Safary A. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine. 15:1997;1732-1736
21. Mahoney F.J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12:1999;351-366
22. Mardiney M.R., Brown M.R., Fleisher T.A. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Cytometry. 26:1996;305-310
23. McNally J.M., Dempsey D., Wolcott R.M., Chervenak R., Jennings S.R. Phenotypic identification of antigen-dependent and antigen-independent CD8 CTL precursors in the draining lymph node during acute cutaneous herpes simplex virus type 1 infection. J. Immunol. 163:1999;675-681
24. Mendes R., Bromelow K.V., Westby M., Galea-Lauri J., Smith I.E., O'Brien M.E., Souberbielle B.E. Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood. Cytometry. 39:2000;72-78
25. Milich D.R., Jones J.E., Hughes J.L., Price J., Raney A.K., McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. U.S.A. 87:1990;6599-6603
26. Ochs H.D., Hollenbaugh D., Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin. Immunol. 6:1994;337-341
27. Shokrgozar M.A., Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology. 104:2001;75-79
28. Shu U., Kiniwa M., Wu C.Y., Maliszewski C., Vezzio N., Hakimi J., Gately M., Delespesse G. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1995;1125-1128
29. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., Sadovsky R., Morrison J.M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303:1980;833-841
30. Testi R., Phillips J.H., Lanier L.L. Constitutive expression of a phosphorylated activation antigen (Leu 23) by CD3bright human thymocytes. J. Immunol. 141:1988;2557-2563
31. Vingerhoets J., Vanham G., Kestens L., Penne G., Leroux-Roels G., Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol. Lett. 39:1994;163-168